The findings in this study describe another anti-cancer property of apigenin to add to the arsenal of existing research having shown its ability to attenuate tumor promoting enzymes [1,2], prevent chemoresistance/multi-drug resistance [3–5], halt angiogenesis [6] lessening VEGF, inhibiting aromatase, proteasomal processes and fatty acid synthase, [18–21] and an overall reduction in proliferation, migration, and invasion of aggressive breast cancer [7]. Here, CYP19A1 is linked to breast cancer.